492 related articles for article (PubMed ID: 16581975)
1. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
[TBL] [Abstract][Full Text] [Related]
2. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
3. Defining "neuroinflammation".
O'Callaghan JP; Sriram K; Miller DB
Ann N Y Acad Sci; 2008 Oct; 1139():318-30. PubMed ID: 18991877
[TBL] [Abstract][Full Text] [Related]
4. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2002 Sep; 16(11):1474-6. PubMed ID: 12205053
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.
Rojo AI; Innamorato NG; Martín-Moreno AM; De Ceballos ML; Yamamoto M; Cuadrado A
Glia; 2010 Apr; 58(5):588-98. PubMed ID: 19908287
[TBL] [Abstract][Full Text] [Related]
7. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
8. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
9. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum.
Ferger B; Leng A; Mura A; Hengerer B; Feldon J
J Neurochem; 2004 May; 89(4):822-33. PubMed ID: 15140182
[TBL] [Abstract][Full Text] [Related]
10. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
11. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
12. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Chung YC; Kim SR; Jin BK
J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
[TBL] [Abstract][Full Text] [Related]
15. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
[TBL] [Abstract][Full Text] [Related]
17. S-allylcysteine reduces the MPTP-induced striatal cell damage via inhibition of pro-inflammatory cytokine tumor necrosis factor-α and inducible nitric oxide synthase expressions in mice.
García E; Villeda-Hernández J; Pedraza-Chaverrí J; Maldonado PD; Santamaría A
Phytomedicine; 2010 Dec; 18(1):65-73. PubMed ID: 20576415
[TBL] [Abstract][Full Text] [Related]
18. The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity.
O'Callaghan JP; Martin PM; Mass MJ
Ann N Y Acad Sci; 1998 May; 844():40-9. PubMed ID: 9668663
[TBL] [Abstract][Full Text] [Related]
19. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
